Roche Holding AG
RO
Company Profile
Business description
Roche is a Swiss biopharmaceutical and diagnostic company. The firm's bestselling pharmaceutical products include a variety of oncology therapies from acquired partner Genentech, and its diagnostics group was bolstered by the acquisition of Ventana in 2008. Oncology products account for 50% of pharmaceutical sales, and centralized and point-of-care diagnostics for more than half of diagnostic-related sales.
Contact
Grenzacherstrasse 124
Basel4070
CHET: +41 616881111
Sector
Healthcare
Stock type
Defensive
Industry
Drug Manufacturers - General
Fiscal Year End
31 December 2025
Employees
103,249
Roche Holding AG News & Analysis
stocks
6 undervalued stocks with low beta
Berkshire Hathaway and Verizon are among the low-volatility stocks that trade at a discount.
stocks
An undervalued, wide-moat name in healthcare
Companies racing for a coronavirus cure have moved to lofty valuations. Morningstar analyst Alex Morozov is looking for lesser-known healthcare names.
Morningstar Investment Ideas
Markets
Index | Last price | Change | % Change |
|---|---|---|---|
| All Ordinaries | 8,937.50 | 41.90 | -0.47% |
| CAC 40 | 7,818.28 | 32.15 | -0.41% |
| DAX 40 | 24,295.93 | 55.11 | 0.23% |
| Dow JONES (US) | 44,693.91 | 316.38 | -0.70% |
| FTSE 100 | 9,138.37 | 76.88 | 0.85% |
| HKSE | 25,383.07 | 284.11 | -1.11% |
| NASDAQ | 21,057.96 | 37.94 | 0.18% |
| Nikkei 225 | 41,450.36 | 375.98 | -0.90% |
| NZX 50 Index | 12,855.10 | 49.97 | 0.39% |
| S&P 500 | 6,363.35 | 4.44 | 0.07% |
| S&P/ASX 200 | 8,670.10 | 39.30 | -0.45% |
| SSE Composite Index | 3,593.38 | 12.35 | -0.34% |